Mechanism

Toll-like receptor 7 (TLR7) (inhibitor)

Assets acting on this target.

Class
Monoclonal antibody (TLR7 antagonist)
Pathway
Innate immune TLR7 signaling
Notes
original target text: Toll-like receptor 7 (TLR7)

Toll-like receptor 7 (TLR7) is a pattern-recognition receptor of the innate immune system that detects single-stranded RNA, normally a signal of viral infection. It resides inside endosomes of specialized immune cells, including plasmacytoid dendritic cells and B lymphocytes, and upon engagement triggers intracellular signaling that culminates in production of type I interferons and pro-inflammatory cytokines. This response is protective during viral infection, but TLR7 can also be activated inappropriately by a person's own RNA-containing material, particularly RNA bound in immune complexes. Chronic, self-directed TLR7 signaling is implicated in autoimmune conditions such as systemic lupus erythematosus, where sustained interferon output and B-cell activation contribute to autoantibody formation and tissue damage. Blocking TLR7, for example with a monoclonal antibody that prevents the receptor from engaging its RNA ligand or from signaling downstream, is a strategy aimed at reducing this pathological innate-immune drive without eliminating the entire immune system. This mechanism is relevant broadly to autoimmune and inflammatory diseases in which excessive nucleic-acid sensing is thought to sustain disease activity, and reflects a wider therapeutic interest in modulating the interferon pathway.

Research

Explore this mechanism at different depths

Research adds deeper and simplified explanation variants while preserving the same scientific register and source caveats.

Company

1 of 1 assets

← all assets